Phase I study of taxol administered as a short i.v. infusion daily for 5 days.

J. L. Grem, K. D. Tutsch, K. J. Simon, D. B. Alberti, J. K. Willson, D. C. Tormey, S. Swaminathan, D. L. Trump

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

Taxol inhibits cell division by promoting the assembly and stabilization of microtubules. This report describes the results of a phase I trial of taxol administered as a short iv infusion daily for 5 days every 4 weeks. Sixteen patients with refractory malignancy received 21 courses of taxol at five doses between 5 and 40 mg/m2/day X 5. The first nine patients received taxol as a 60-minute infusion. Two patients experienced anaphylactoid reactions, one at the 5-mg/m2/day and the second at the 15-mg/m2/day X 5 dose levels. These reactions were characterized by facial flushing, tachypnea, and hypotension within several minutes of drug administration. These anaphylactoid reactions occurred on the first day of treatment in the first patient and on the first day of the second course in the second patient. These reactions may be related to the rapid administration of the polyoxyethylated castor oil (Cremophor EL) vehicle in which taxol is formulated. No anaphylactoid reactions were observed in the seven patients who received taxol as a 6-hour infusion with antihistamine and prednisone premedication. Dose-related myelosuppression was seen; leukopenia (wbc count less than 1000/mm3) and granulocytopenia (granulocytes less than or equal to 200/mm3) occurred on Days 8 and 9 in two of two patients treated at the 40 mg/m2/day X 5 level. Thrombocytopenia was mild, with a platelet nadir of 87,000-95,000/mm3 at the highest dose level. Premedication with glucocorticoids and antihistamines coupled with a prolonged 6-hour infusion permitted taxol to be administered at 30 mg/m2/day X 5 safely without immediate life-threatening reactions.

Original languageEnglish (US)
Pages (from-to)1179-1184
Number of pages6
JournalCancer treatment reports
Volume71
Issue number12
StatePublished - Dec 1987

Fingerprint

Paclitaxel
Premedication
Histamine Antagonists
Castor Oil
Tachypnea
Agranulocytosis
Leukopenia
Prednisone
Granulocytes
Microtubules
Thrombocytopenia
Cell Division
Hypotension
Glucocorticoids
Blood Platelets
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Grem, J. L., Tutsch, K. D., Simon, K. J., Alberti, D. B., Willson, J. K., Tormey, D. C., ... Trump, D. L. (1987). Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer treatment reports, 71(12), 1179-1184.

Phase I study of taxol administered as a short i.v. infusion daily for 5 days. / Grem, J. L.; Tutsch, K. D.; Simon, K. J.; Alberti, D. B.; Willson, J. K.; Tormey, D. C.; Swaminathan, S.; Trump, D. L.

In: Cancer treatment reports, Vol. 71, No. 12, 12.1987, p. 1179-1184.

Research output: Contribution to journalArticle

Grem, JL, Tutsch, KD, Simon, KJ, Alberti, DB, Willson, JK, Tormey, DC, Swaminathan, S & Trump, DL 1987, 'Phase I study of taxol administered as a short i.v. infusion daily for 5 days.', Cancer treatment reports, vol. 71, no. 12, pp. 1179-1184.
Grem JL, Tutsch KD, Simon KJ, Alberti DB, Willson JK, Tormey DC et al. Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer treatment reports. 1987 Dec;71(12):1179-1184.
Grem, J. L. ; Tutsch, K. D. ; Simon, K. J. ; Alberti, D. B. ; Willson, J. K. ; Tormey, D. C. ; Swaminathan, S. ; Trump, D. L. / Phase I study of taxol administered as a short i.v. infusion daily for 5 days. In: Cancer treatment reports. 1987 ; Vol. 71, No. 12. pp. 1179-1184.
@article{a2a1d3849e6e441e991fa4728d99ffaa,
title = "Phase I study of taxol administered as a short i.v. infusion daily for 5 days.",
abstract = "Taxol inhibits cell division by promoting the assembly and stabilization of microtubules. This report describes the results of a phase I trial of taxol administered as a short iv infusion daily for 5 days every 4 weeks. Sixteen patients with refractory malignancy received 21 courses of taxol at five doses between 5 and 40 mg/m2/day X 5. The first nine patients received taxol as a 60-minute infusion. Two patients experienced anaphylactoid reactions, one at the 5-mg/m2/day and the second at the 15-mg/m2/day X 5 dose levels. These reactions were characterized by facial flushing, tachypnea, and hypotension within several minutes of drug administration. These anaphylactoid reactions occurred on the first day of treatment in the first patient and on the first day of the second course in the second patient. These reactions may be related to the rapid administration of the polyoxyethylated castor oil (Cremophor EL) vehicle in which taxol is formulated. No anaphylactoid reactions were observed in the seven patients who received taxol as a 6-hour infusion with antihistamine and prednisone premedication. Dose-related myelosuppression was seen; leukopenia (wbc count less than 1000/mm3) and granulocytopenia (granulocytes less than or equal to 200/mm3) occurred on Days 8 and 9 in two of two patients treated at the 40 mg/m2/day X 5 level. Thrombocytopenia was mild, with a platelet nadir of 87,000-95,000/mm3 at the highest dose level. Premedication with glucocorticoids and antihistamines coupled with a prolonged 6-hour infusion permitted taxol to be administered at 30 mg/m2/day X 5 safely without immediate life-threatening reactions.",
author = "Grem, {J. L.} and Tutsch, {K. D.} and Simon, {K. J.} and Alberti, {D. B.} and Willson, {J. K.} and Tormey, {D. C.} and S. Swaminathan and Trump, {D. L.}",
year = "1987",
month = "12",
language = "English (US)",
volume = "71",
pages = "1179--1184",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Phase I study of taxol administered as a short i.v. infusion daily for 5 days.

AU - Grem, J. L.

AU - Tutsch, K. D.

AU - Simon, K. J.

AU - Alberti, D. B.

AU - Willson, J. K.

AU - Tormey, D. C.

AU - Swaminathan, S.

AU - Trump, D. L.

PY - 1987/12

Y1 - 1987/12

N2 - Taxol inhibits cell division by promoting the assembly and stabilization of microtubules. This report describes the results of a phase I trial of taxol administered as a short iv infusion daily for 5 days every 4 weeks. Sixteen patients with refractory malignancy received 21 courses of taxol at five doses between 5 and 40 mg/m2/day X 5. The first nine patients received taxol as a 60-minute infusion. Two patients experienced anaphylactoid reactions, one at the 5-mg/m2/day and the second at the 15-mg/m2/day X 5 dose levels. These reactions were characterized by facial flushing, tachypnea, and hypotension within several minutes of drug administration. These anaphylactoid reactions occurred on the first day of treatment in the first patient and on the first day of the second course in the second patient. These reactions may be related to the rapid administration of the polyoxyethylated castor oil (Cremophor EL) vehicle in which taxol is formulated. No anaphylactoid reactions were observed in the seven patients who received taxol as a 6-hour infusion with antihistamine and prednisone premedication. Dose-related myelosuppression was seen; leukopenia (wbc count less than 1000/mm3) and granulocytopenia (granulocytes less than or equal to 200/mm3) occurred on Days 8 and 9 in two of two patients treated at the 40 mg/m2/day X 5 level. Thrombocytopenia was mild, with a platelet nadir of 87,000-95,000/mm3 at the highest dose level. Premedication with glucocorticoids and antihistamines coupled with a prolonged 6-hour infusion permitted taxol to be administered at 30 mg/m2/day X 5 safely without immediate life-threatening reactions.

AB - Taxol inhibits cell division by promoting the assembly and stabilization of microtubules. This report describes the results of a phase I trial of taxol administered as a short iv infusion daily for 5 days every 4 weeks. Sixteen patients with refractory malignancy received 21 courses of taxol at five doses between 5 and 40 mg/m2/day X 5. The first nine patients received taxol as a 60-minute infusion. Two patients experienced anaphylactoid reactions, one at the 5-mg/m2/day and the second at the 15-mg/m2/day X 5 dose levels. These reactions were characterized by facial flushing, tachypnea, and hypotension within several minutes of drug administration. These anaphylactoid reactions occurred on the first day of treatment in the first patient and on the first day of the second course in the second patient. These reactions may be related to the rapid administration of the polyoxyethylated castor oil (Cremophor EL) vehicle in which taxol is formulated. No anaphylactoid reactions were observed in the seven patients who received taxol as a 6-hour infusion with antihistamine and prednisone premedication. Dose-related myelosuppression was seen; leukopenia (wbc count less than 1000/mm3) and granulocytopenia (granulocytes less than or equal to 200/mm3) occurred on Days 8 and 9 in two of two patients treated at the 40 mg/m2/day X 5 level. Thrombocytopenia was mild, with a platelet nadir of 87,000-95,000/mm3 at the highest dose level. Premedication with glucocorticoids and antihistamines coupled with a prolonged 6-hour infusion permitted taxol to be administered at 30 mg/m2/day X 5 safely without immediate life-threatening reactions.

UR - http://www.scopus.com/inward/record.url?scp=0023477883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023477883&partnerID=8YFLogxK

M3 - Article

C2 - 2891442

AN - SCOPUS:0023477883

VL - 71

SP - 1179

EP - 1184

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 12

ER -